	US 11,814,437 B2
	Antibodies binding to CD30 and CD3
David Satijn, Utrecht (NL); Patrick Engelberts, Amersffoort (NL); Kristel Kemper, Utrecht (NL); Esther C. W. Breij, Driebergen (NL); Simone Oostindie, Utrecht (NL); and Farshid Alemdehy, Utrecht (NL)
Assigned to GENMAB A/S, Valby (DK)
Filed by GENMAB A/S, Valby (DK)
Filed on Oct. 6, 2022, as Appl. No. 17/938,523.
Claims priority of application No. 21201712 (EP), filed on Oct. 8, 2021.
Prior Publication US 2023/0132049 A1, Apr. 27, 2023
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); C12N 15/63 (2006.01)

CPC C07K 16/2878 (2013.01) [A61P 35/00 (2018.01); C07K 16/2809 (2013.01); C12N 15/63 (2013.01); C07K 2317/31 (2013.01); C07K 2317/526 (2013.01); C07K 2317/565 (2013.01)]

16 Claims

1. A bispecific antibody comprising a CD30 binding region comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 17 and a first light chain comprising the amino acid sequence of SEQ ID NO: 18, and a CD3 binding region comprising a second heavy chain comprising the amino acid sequence of SEQ ID NO: 19 and a second light chain comprising the amino acid sequence of SEQ ID NO: 20.